Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing

被引：0
|
作者：
Kavanaugh, Arthur [1 ]
McInnes, Iain B. [2 ]
Mease, Philip J. [3 ]
Hall, Stephan [4 ]
Chinoy, Hector [5 ]
Kivitz, Alan J. [6 ]
Patekar, Manmath [7 ]
Wang, Zailong [8 ]
Mpofu, Shephard [9 ]
机构：
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[2] Univ Glasgow, Immunol Infect & Inflammat, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Rheumatol Res, Seattle, WA USA
[4] Monash Univ, Melbourne, Vic 3004, Australia
[5] Univ Manchester, Manchester, Lancs, England
[6] Altoona Ctr Clin Res, Duncansville, PA USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2146
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naive Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Subramanian, Ramanand
    Agarwal, Prasheen
    Sheng, Shihong
    Zhou, Bei
    van der Heijde, Desiree
    McInnes, Iain
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [42] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 24 RESULTS OF THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice
    Hsia, Elizabeth
    Kollmeier, Alexa P.
    Xu, Xie L.
    Subramanian, Ramanand A.
    Agarwal, Prasheen
    Sheng, Shihong
    Zhou, Bei
    van der Helide, Desiree
    Zazzetti, Federico
    McInnes, Lin B.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 23 - 23
  • [43] EFFICACY AND SAFETY OF SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED GLOBAL PHASE 3 STUDY (SIRROUND-T)
    Pile, K.
    Aletaha, D.
    Tanaka, Y.
    Agarwal, P.
    Kurrasch, R.
    Tak, P.
    Popik, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 27 - 27
  • [44] SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY
    Kirkham, Bruce
    Mease, Philip J.
    McInnes, Iain B.
    RHEUMATOLOGY, 2017, 56 : 77 - 77
  • [45] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
    Deodhar, Atul
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Subramanian, Ramanand A.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    Ritchlin, Christopher T.
    LANCET, 2020, 395 (10230): : 1115 - 1125
  • [46] Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis
    Chen, Der-Yuan
    Chou, Show-Jan
    Hsieh, Tsu-Yi
    Chen, Yi-Hsing
    Chen, Hsin-Hua
    Hsieh, Chia-Wei
    Lan, Joung-Liang
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (04) : 310 - 319
  • [47] A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study.
    Kavanaugh, Arthur
    Decktor, Dennis L.
    Fan, Chunpeng
    van Adelsberg, Janet
    Martincova, Renata
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1233 - S1234
  • [48] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    McInnes, Iain B.
    Mease, Philip J.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Rahman, Proton
    Van der Heijde, Desiree
    Landewe, Robert
    Conaghan, Philip G.
    Gottlieb, Alice B.
    Richards, Hanno
    Pricop, Luminita
    Ligozio, Gregory
    Patekar, Manmath
    Mpofu, Shephard
    LANCET, 2015, 386 (9999): : 1137 - 1146
  • [49] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naive or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Deodhar, Atul
    Helliwell, Philip
    Boencke, Wolf-Henning
    Hsia, Elizabeth
    Kollmeier, Alexa
    Subramanian, Ramanand
    Xu, Xie
    Sheng, Shihong
    Zhou, Bei
    Ritchlin, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [50] SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, PROVIDES SIGNIFICANT AND SUSTAINED INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF PRIOR TNF INHIBITORS OR CONCOMITANT METHOTREXATE: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Collins, A.
    Van Der Heijde, D.
    Landewe, R.
    Mease, P.
    McInnes, I.
    Conaghan, P.
    Pricop, L.
    Ligozio, G.
    Richards, H.
    Mpofu, S.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 42 - 43
12345